Patients with ASPSCR1-TFE3 fusion achieve better response to ICI based combination therapy among TFE3-rearranged renal cell carcinoma

Abstract Background TFE3-rearranged renal cell carcinoma (TFE3-rRCC) is a rare but highly heterogeneous renal cell carcinoma (RCC) entity, of which the clinical treatment landscape is largely undefined. This study aims to evaluate and compare the efficacy of different systemic treatments and further...

Повний опис

Бібліографічні деталі

Автори:	Junjie Zhao, Yanfeng Tang, Xu Hu, Xiaoxue Yin, Yuntian Chen, Junru Chen, Haoyang Liu, Haolin Liu, Jiayu Liang, Xingming Zhang, Jinge Zhao, Sha Zhu, Yuchao Ni, Zhipeng Wang, Jindong Dai, Zilin Wang, Yaowen Zhang, Jin Yao, Ni Chen, Pengfei Shen, Zhenhua H. Liu, Hao Zeng, Guangxi X. Sun
Формат:	Artigo
Мова:	Inglês
Опубліковано:	BMC 2024-06-01
Серія:	Molecular Cancer
Предмети:	TFE3-rRCC Fusion partner ASPSCR1 Immune checkpoint inhibitor Combination therapy Molecular correlates
Онлайн доступ:	https://doi.org/10.1186/s12943-024-02044-5
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!